未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
Le Tourneau, Christophe; Delord, Jean-Pierre; Kotecki, Nuria; Borcoman, Edith; Gomez-Roca, Carlos; Hescot, Segolene; Jungels, Christiane; Vincent-Salomon, Anne; Cockenpot, Vincent; Eberst, Lauriane; Mole, Audrey; Jdey, Wael; Bono, Francoise; Trochon-Joseph, Veronique; Toussaint, Helene; Zandanel, Christelle; Adamiec, Olga; de Beaumont, Olivier; Cassier, Philippe Alexandre
分享
收藏
分享
收藏
分享
收藏Phase I dose escalation study evaluating the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AsiDNA, a first-in-class DNA Repair Inhibitor, administered intravenously (IV) in patients with advanced solid tumors
Le Tourneau, Christophe; Delord, Jean-Pierre; Cassier, Philippe; Kotecki, Nuria; Borcoman, Edith; Hescot, Segolene; Jungels, Christiane; Mole, Audrey; Toussaint, Helene; Adamiec, Olga; de Beaumont, Olivier
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients
Nony, E.; Bouley, J.; Le Mignon, M.; Lemoine, P.; Jain, K.; Horiot, S.; Mascarell, L.; Pallardy, M.; Vincentelli, R.; Leone, P.; Roussel, A.; Batard, T.; Abiteboul, K.; Robin, B.; de Beaumont, O.; Arvidsson, M.; Rak, S.; Moingeon, P.
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Allergen-specific CD4+T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy
Bonvalet, M.; Moussu, H.; Wambre, E.; Ricarte, C.; Horiot, S.; Rimaniol, A-C; Kwok, W. W.; Horak, F.; de Beaumont, O.; Baron-Bodo, V.; Moingeon, P.
分享
收藏